A Message from Dr. Allyson Berent:

It is a tremendous honor to share with you some great news. 

In the last year, numerous programs in the Angelman syndrome drug development pipeline have matured to the point where they are ready for further development, exploration, and acceleration toward clinical trials. This means we have crossed a threshold with numerous programs, requiring me to focus on this particular area of research, which is what I am most passionate about. This involves assessing whether each potential therapeutic can advance from a promising drug candidate in animals to the next stage of evaluation in a human clinical trial, and then ensuring programs are rigorously designed and executed to achieve this goal. We have been dreaming about getting to this point for a long time, and we are finally here.  

To this end, I’ll be splitting my time between FAST and our new accelerator, AS2Bio, which you can read more about HERE. I will continue to serve as FAST’s Chief Science Officer, focusing on IND-enabling studies and getting numerous programs farther through the pipeline toward human application, but in partnership with Dr. Edwin Weeber as head of research and discovery.

Ed has a long history not just with Angelman syndrome, but with FAST. To start with, he led pioneering initiatives aimed at ameliorating the symptoms in the Angelman syndrome mouse model. Through a multifaceted approach encompassing genetic interventions, protein supplementation strategies, and gene therapy techniques, his groundbreaking work shed light on the underlying mechanisms of the disorder and the potential for therapeutic intervention. In addition, he helmed the first AS consortium of scientists from different specialties and academic laboratories to collaborate and focus on discovering potential therapies for AS. This collaborative effort was dedicated to the development of promising therapeutic avenues. Please join us in extending a warm welcome back to FAST for Ed as he continues his valuable contributions to the AS community! 

Meet Dr. Weeber:

The 4th annual International Angelman Syndrome Research Council (INSYNC) meeting was held last week at the Simons Foundation’s headquarters in New York City. Organized jointly by the Simons Foundation and FAST, this event brought FAST together with the Simons Foundation Autism Research Initiative (SFARI), industry sponsors, regulatory experts, invited speakers and representatives from FAST and other rare monogenic neurodevelopmental disorder groups.

This meeting serves as a platform to provide pre-competitive, comprehensive insights into the landscape of Angelman syndrome research with a focus on rare disease therapeutic development. 

Read more about this year’s event here:

Derrick and Johnna Webb hosted the 11th Annual Harper’s Hope Golf Scramble on June 1st in Louisa, Kentucky in honor of their daughter, Harper, who lives with Angelman syndrome. It was a tremendous success as more than 100 golfers participated in games both on and off the golf course to raise critical funds to support the Foundation for Angelman Syndrome Therapeutics.  

Read more about this event:

Reminder: the deadline for FAST Global Science Summit & Gala Scholarship Applications is June 19th at 11:45pm CT. 

Apply today:

Thanks for reading, and please share this email with anyone in your network who would be interested in receiving our updates.